ESPR - Esperion Therapeutics, Inc.

QQQ $ 440.32 $ 0.07 (0.02 %)

DIA $ 388.70 $ 0.29 (0.07 %)

SPY $ 517.26 $ 0.57 (0.11 %)

TLT $ 90.79 $ 0.55 (0.61 %)

GLD $ 214.23 $ -0.99 (-0.46 %)

Previous Close

$ 2.37

Open

$ 2.53

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.14 - $ 2.55

52 Week Range

$ 0.70 - $ 3.40

Volume

45,750,198

Average Volume

Market Cap

449.45M

Beta (5Y Monthly)

$ 0.86

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-07-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-01-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	02-21-2023	12-31-2022	10-K
7	11-01-2022	09-30-2022	10-Q
8	08-02-2022	06-30-2022	10-Q
9	05-03-2022	03-31-2022	10-Q
10	02-22-2022	12-31-2021	10-K
11	11-02-2021	09-30-2021	10-Q
12	08-03-2021	06-30-2021	10-Q
13	05-04-2021	03-31-2021	10-Q
14	02-23-2021	12-31-2020	10-K
15	11-02-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-06-2020	03-31-2020	10-Q
18	02-27-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-08-2019	03-31-2019	10-Q
22	02-28-2019	12-31-2018	10-K
23	11-01-2018	09-30-2018	10-Q
24	08-02-2018	06-30-2018	10-Q
25	05-02-2018	03-31-2018	10-Q
26	02-20-2018	12-31-2017	10-K
27	11-07-2017	09-30-2017	10-Q
28	08-08-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	02-22-2017	12-31-2016	10-K
31	11-03-2016	09-30-2016	10-Q
32	08-04-2016	06-30-2016	10-Q
33	05-04-2016	03-31-2016	10-Q
34	02-25-2016	12-31-2015	10-K
35	11-05-2015	09-30-2015	10-Q
36	08-06-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	03-10-2015	12-31-2014	10-K
39	11-10-2014	09-30-2014	10-Q
40	08-12-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Needham Reiterates Buy on Esperion Therape...
05/07/2024 17:57:08

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.

heart-disease-drugmaker-esperion-therapeutics-reports-highest-revenue-yet-stock-soars

Heart Disease Drugmaker Esperion Therapeut...
05/07/2024 14:20:54

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA...

CORRECTION: Esperion Therapeutics Sees FY2...
05/07/2024 14:19:57

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
05/07/2024 12:06:20

Esperion Therapeutics Q1 EPS $0.34 Beats $...
05/07/2024 10:02:52

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of...

applied-digital-reports-downbeat-results-joins-nurix-therapeutics-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

Applied Digital Reports Downbeat Results, ...
04/12/2024 12:04:19

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.

Why Fastenal Shares Are Trading Lower By A...
04/11/2024 17:33:07

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

Needham Reiterates Buy on Esperion Therape...
04/10/2024 10:48:57

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.

why-esperion-therapeutics-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket

Why Esperion Therapeutics Shares Are Tradi...
04/08/2024 09:15:51

Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company ...

Reported Sunday, Esperion Presents New Dat...
04/08/2024 06:41:53

Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compa...

Why Ulta Beauty Shares Are Trading Lower B...
04/03/2024 17:56:10

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...

signet-jewelers-dave--busters-entertainment-blue-owl-capital-and-other-big-stocks-moving-higher-on-wednesday

Signet Jewelers, Dave & Buster's Entertain...
04/03/2024 14:31:14

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.

Esperion Announces Data from CLEAR Outcome...
03/25/2024 20:01:14

why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Landos Biopharma Shares Are Trading Hi...
03/25/2024 18:44:08

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

HC Wainwright & Co. Reiterates Buy on Espe...
03/25/2024 17:01:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16...

why-is-heart-disease-focused-esperion-therapeutics-stock-trading-higher-on-monday

Why Is Heart Disease-Focused Esperion Ther...
03/25/2024 13:24:01

Latest FDA-approved label expansions for Esperion Therapeutics' NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic a...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
03/25/2024 13:05:53

Market-Moving News for March 25th
03/25/2024 12:40:17

MLGO: 102% | MicroAlgo Inc. Announced a Deep Clustering Algorithm Based on Multi-level Feature Fusion MASI: 15% | Masmi shares...

why-salarius-pharmaceuticals-shares-are-trading-higher-by-around-31-here-are-20-stocks-moving-premarket

Why Salarius Pharmaceuticals Shares Are Tr...
03/25/2024 12:03:24

Shares of Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) rose sharply in today’s pre-market trading following fourth-quarter re...

Needham Reiterates Buy on Esperion Therape...
03/25/2024 11:35:04

Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $8 price target.